FRANKLIN LAKES, N.J.,
Feb. 22, 2021 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, and Scanwell Health, a leader in
smartphone-enabled at-home medical tests, today announced a
collaboration to create an at-home rapid test for SARS-CoV-2 using
a BD antigen test and the Scanwell Health mobile app.
As part of the collaboration, BD plans to produce a lateral flow
antigen test and pair it with the Scanwell Health mobile app. The
app is expected to provide step-by-step instructions on how to
collect and transfer a nasal swab sample and use the mobile
device's camera to analyze and interpret results. The test result
will be displayed onscreen, and the companies are also planning to
develop functionality to assist in automated reporting to public
health agencies. This approach is intended to provide an efficient
and scalable rapid antigen home testing solution.
"Testing at home before going out into the public is a critical
safeguard to help stop the spread of COVID-19," said Dave Hickey, president of Life Sciences for BD.
"BD and Scanwell Health are bringing the best of our innovations
together to develop a reliable test with a convenient and simple
user experience. We see the development of an at-home lateral flow
rapid antigen test as a complementary solution to our best-in-class
BD Veritor™ system."
Stephen Chen, founder and CEO of
Scanwell Health said, "Partnering with an industry leader like BD
creates a unique opportunity to help millions of people test for
the SARS-CoV-2 virus from the safety and comfort of their homes.
Scanwell's innovative computer vision technology closely mirrors
that of point-of-care and laboratory diagnostic systems. We're
excited to leverage our experience in building FDA-cleared apps to
bring this solution to market."
BD has been on the forefront of the COVID-19 response providing
innovative solutions for immunology research, molecular- and
antigen-based diagnostics, devices that aid in therapeutics and
injection devices for vaccine administration.
About BD Veritor™ Plus System for Rapid Detection of
SARS-CoV-2
The BD Veritor™ Plus System for Rapid Detection
of SARS-CoV-2 Assay has not been cleared or approved by FDA. The
test has been authorized by FDA under an EUA for use by authorized
laboratories. The test has been authorized only for the detection
of proteins from SARS-CoV-2, not for any other viruses or
pathogens; and, the test is only authorized for the duration of the
declaration that circumstances exist justifying the authorization
of emergency use of in vitro diagnostics for detection and/or
diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C.
§ 360bbb-3(b)(1), unless the authorization is terminated or revoked
sooner. For more information on the BD Veritor™ system, please
visit bdveritor.com
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 70,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please visit
bd.com or connect with us on LinkedIn at
www.linkedin.com/company/bd1/ and Twitter @BDandCo.
About Scanwell Health
Scanwell Health empowers health
care consumers and companies through at-home medical testing with
instant results. Scanwell pairs proven diagnostics with patented
computer vision technology to put testing into the hands of people,
enabling quick detection of acute illnesses and convenient
monitoring of chronic diseases. The company is the first and only
to receive FDA 510(k) clearance for an over-the-counter diagnostic
smartphone application. Learn more at scanwellhealth.com.
Forward-Looking Statements
This press release
contains certain forward-looking statements regarding the
development of the BD at-home COVID-19 diagnostic test.
Forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from those
expressed or implied in such statements. Many of these risks
and uncertainties are beyond the company's control, including
without limitation, challenges inherent in product development and
risks relating to regulatory compliance of any test that may be
developed, disruptions caused by the coronavirus pandemic and other
factors listed in our 2020 Annual Report on Form 10-K and other
filings with the SEC. BD expressly disclaims any undertaking to
update any forward-looking statements set forth herein to reflect
events or circumstances after the date hereof, except as required
by applicable laws or regulations.
Contacts:
|
|
|
|
Troy
Kirkpatrick
|
Candace
Kim
|
BD Public
Relations
|
Scanwell Public
Relations
|
858.617.2361
|
775.233.7846
|
troy.kirkpatrick@bd.com
|
candace@scanwellhealth.com
|
|
|
Kristen M. Stewart,
CFA
|
|
BD Investor
Relations
|
|
201.847.5378
|
|
kristen.stewart@bd.com
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bd-announces-collaboration-for-at-home-rapid-test-for-covid-19-301232057.html
SOURCE BD (Becton, Dickinson and Company)